I54.F BIOCYTOGEN PHARMA. H YC1

Healthcare Biotechnology Frankfurt Exchange
20.63 EUR
Close of Nov 12, 2026
2.78 8.90
Market cap
EUR 2.22B
P/E
50.0x
P/B
6.71x
ROE
8.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is I54.F undervalued?

Graham number

The Graham number of BIOCYTOGEN PHARMA. H YC1 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOCYTOGEN PHARMA. H YC1 fundamental analysis

No fundamental analysis for BIOCYTOGEN PHARMA. H YC1 yet.

BIOCYTOGEN PHARMA. H YC1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOCYTOGEN PHARMA. H YC1

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs …

Full company profile